



ROMA

HEMATOLOGY
CONFERENCE
the lymphomas

Rome

October 15-16, 2026

Hotel nhow Roma Vittorio Veneto

October 15, 2026

13.30 Introduction

S. Hohaus (Roma), M. Martelli (Roma), L. Rigacci (Roma)

Greetings from the President of the Italian Society of Hematology

P.L. Zinzani (Bologna)

13.45 40 years of hematology in 'Via Benevento'

M. Martelli (Roma)

SESSION I BASIC/TRANSLATIONAL SCIENCE SHAPING THE FUTURE OF TARGETED THERAPIES IN LYMPHOMA

Chairmen: R. Foà (Roma), G. Gaidano (Novara)

14.15 Introductory key lecture: the biology of B-cell lymphomas

R. Dalla Favera (New York, USA)

14.35 Genomic/molecular profiling of non-Hodgkin lymphomas (NGS, ctDNA)

D. Rossi (Bellinzona, CH)

14.55 Genomic/molecular profiling of Hodgkin lymphomas (NGS, ctDNA)

E. Tiacci (Perugia)

15.15 Signaling pathways and microenvironment crosstalk in lymphomas

S. Casola (Milano)

15.35 Biologic insights into MCL from the MCL0208 study

S. Ferrero (Torino)

15.55 Round Table - Which are emerging targets in lymphomas?

Chairmen: A. Di Napoli (Roma), D. Remotti (Viterbo)

Discussants: S. Casola (Milano), R. Dalla Favera (New York, USA),

S. Ferrero (Torino), C. Giordano (Roma), D. Rossi (Bellinzona, CH),

E. Tiacci (Perugia)

16.25 *Coffee Break*

SESSION II ACADEMIC RESEARCH LEADING TO CHANGE IN CLINICAL PRACTICE: THREE MILESTONES

Chairmen: S. Hohaus (Roma), M. Ladetto (Alessandria)

16.40 Interim FDG-PET in advanced classical Hodgkin lymphoma: will the story continue?

M. Hutchings (Copenhagen, DK)

17.00 Primary central nervous system lymphoma form radiotherapy to chemotherapy ... to targeted therapy?

A.J.M. Ferreri (Milano)

17.20 Primary mediastinal B-cell lymphoma

M. Martelli (Roma)

17.40 Round Table - How can academic research contribute to the progress in lymphoma treatment in the future?
Chairmen: R. Foà (Roma), M.C. Cox (Roma)
Discussants: A.J.M. Ferreri (Milano), M. Hutchings (Copenhagen, DK), M. Martelli (Roma)

18.20 Conclusioni prima giornata

October 16, 2026

SESSION III CHANGING TREATMENT ALGORITHMS IN TREATMENT OF AGGRESSIVE LYMPHOMAS

Chairmen: P. Corradini (Milano), M. Martino (Reggio Calabria)

- 08.00** Introductory key lecture: rethinking treatment algorithms in aggressive B-cell lymphomas
L. Sehn (Vancouver, CAN)
- 08.20** Novel pharmacological paradigms in aggressive B-cell lymphomas
G. Minotti (Roma)
- 08.40** Antibody non drug and drug-conjugated
C. Carlo-Stella (Rozzano-MI)
- 09.00** CAR-T in follicular and DLBC lymphoma
A. Di Rocco (Roma)
- 09.20** CAR-T in difficult-to-target lymphomas: T-cell lymphoma and Hodgkin's lymphoma
F. Locatelli (Roma)
- 09.40** Bispecific antibodies in aggressive lymphomas
R. Di Blasi (Paris, FR)
- 10.00** Round table - Sequencing of targeted therapies: What comes first?
Chairmen: S. Hohaus (Roma), U. Vitolo (Candiolo-TO)
Discussants: C. Carlo-Stella (Rozzano-MI), R. Di Blasi (Paris, FR), A. Di Rocco (Roma), F. Locatelli (Roma), G. Minotti (Roma), L. Sehn (Vancouver, CAN)
- 10.20** Coffee break

SESSION IV DIFFICULT-TO-DIAGNOSE AND DIFFICULT-TO-TREAT LYMPHOMAS

Chairmen: M. Spina (Aviano-PN), U. Vitolo (Candiolo-TO)

- 10.35** Introductory key lecture: aggressive B-cell lymphomas
B. Chapuy (Berlin, DE)
- 10.55** Gray-zone lymphomas
- Diagnosis – **C. Agostinelli (Bologna)**
 - Treatment – **A. Broccoli (Bologna)**



- 11.35** The double-hit and the double expressor
- Diagnosis – **A. Di Napoli (Roma)**
 - Treatment – **M. Balzarotti (Milano)**
- 12.15** Mantle cell lymphoma with poor prognosis (blastoid morphology, p53 mutation, high proliferation index): How can we exploit target therapies (BTKi, BCL2i, T-cell-engagers)?
C. Visco (Verona)
- 12.35** Peripheral T-cell lymphomas
- Diagnosis – **S.A. Pileri (Bologna)**
 - Treatment – **B. Pro (New York, USA)**
- 13.15** Round table: what are the biologic risk factors and how do we stratify our therapy?
Chairmen: A. Broccoli (Bologna), S.A. Pileri (Bologna)
Discussants: C. Agostinelli (Bologna), M. Balzarotti (Milano), B. Chapuy (Berlin, DE), A. Di Napoli (Roma), C. Giordano (Roma), S.A. Pileri (Bologna), B. Pro (New York, USA)

13.35–14.30 *Lunch*

SESSION V LYMPHOMAS WITH GOOD PROGNOSIS: DO NOT HARM

Chairmen: L. Arcaini (Pavia), G. Gini (Ancona)

- 14.30** Introductory key lecture: the indolent lymphomas
C. Thieblemont (Paris, FR)
- 14.50** Follicular lymphoma
S. Montoto (London, UK)
- 15.10** Marginal zone lymphoma
E. Zucca (Bellinzona, CH)
- 15.30** Bispecific antibodies in indolent lymphomas
A. Conconi (Biella)
- 15.50** Localized Hodgkin lymphoma: reduce toxic events while maintaining outstanding results
U. Ricardi (Torino)
- 16.10** Advanced Hodgkin lymphoma: how to choose first-line therapy to achieve the 90% cure goal
A. Pinto (Napoli)
- 16.30** Round table - Does target therapy mean 'no harm'?
Chairmen: A. Pulsoni (Roma), L. Rigacci (Roma)
Discussants: A. Conconi (Biella), S. Montoto (London, UK), A. Pinto (Napoli), U. Ricardi (Torino), C. Thieblemont (Paris, FR), E. Zucca (Bellinzona, CH)
- 16.50** Conclusions
S. Hohaus (Roma), M. Martelli (Roma), L. Rigacci (Roma)

GENERAL INFORMATION

MEETING VENUE

Hotel nhow Roma Vittorio Veneto
Corso d'Italia, 1 - 00198 Roma
Tel. +39 06 84951

REGISTRATION

Registration is available at www.ercongressi.it - section "I nostri congressi/anno 2026"
The registration fee includes: conference kit, participation in the scientific sessions, certificate of attendance, coffee break, lunch, slides of the meeting.

ITALIAN CME CREDITS

An Italian CME application has been submitted as follows:

- Provider Studio ER Congressi SRL: ID 828- 478530.
- No. 8,4 CME credits for Physicians (Hematology; Oncology; Pathological Anatomy; Clinical pathology).
- Educational objective: linee guida- protocolli-procedure.

OFFICIAL LANGUAGE

Italian and English

ORGANIZING SECRETARIAT

Studio ER Congressi

Via De' Poeti, 1/7 - 40124 Bologna
Tel. +39 051 4210559
E-mail: ercongressi@ercongressi.it
www.ercongressi.it

ER Congressi

SCIENTIFIC SECRETARIAT

Maurizio Martelli
Università degli Studi di Roma
"La Sapienza", Roma

Stefan Hohaus
Fondazione Policlinico A. Gemelli, Roma

Luigi Rigacci
Fondazione Policlinico Universitario
Campus Bio-Medico, Roma

SCIENTIFIC COMMITTEE

Ombretta Annibali
Fondazione Policlinico Universitario
Campus Bio-Medico, Roma

Maria Cantonetti
Fondazione Policlinico Tor Vergata,
Roma

Maria Christina Cox
Fondazione Policlinico Tor Vergata,
Roma

Francesco D'Alò
Fondazione Policlinico A. Gemelli, Roma

Alice Di Rocco
Università degli Studi di Roma
"La Sapienza", Roma

Sabrina Pelliccia
Azienda Ospedaliero-Universitaria
Sant'Andrea, Roma



AUSPICES

AIL – Associazione Italiana contro le leucemie - linfomi e mieloma ONLUS

AIL ROMA – Associazione Italiana contro le leucemie - linfomi e mieloma ONLUS – sezione Roma

FIL – Fondazione Italiana Linfomi

GITMO – Gruppo Italiano per il Trapianto di Midollo Osseo, cellule staminali emopoietiche e terapia cellulare

IELSG – International Extranodal Lymphoma Study Group

SIE – Società Italiana di Ematologia

SIES – Società Italiana di Ematologia Sperimentale

With the unrestricted educational grant of

abbvie

 **BeOne**

 **GILEAD**

 **Kite**

Johnson&Johnson

 **Incyte**

 **SOLVE
ON.**

 **Roche**